0
0
0
0
1
2
3
$0
Is ResMed/ solid or fragile? The Finex Financial Health Scanner reads RMD's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2026) | $5.7B |
|---|---|
| Net income | $1.5B |
| Operating margin | 33.4% |
| Net margin | 26.9% |
| Cash and investments | $1.5B |
| Total debt | $659.4M |
| Free cash flow | $1.3B |
| Revenue growth (1 year) | 9.9% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.